BALTRUŠKEVIČIENĖ, E. et al. Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience. Acta medica Lituanica, v. 23, n. 1, p. 24–34, 7 Apr.2016.